Cannabigerol, or CBG, is one of many cannabinoids found in the plant Cannabis sativa. It is a minor constituent, typically present in concentrations of less than 1%, and like other cannabinoids, it interacts with the endocannabinoid system in the human brain and body. 

CBG has been found to have a range of potential therapeutic effects, including anti-inflammatory properties and the potential to treat symptoms of glaucoma. In animal studies, CBG has been shown to reduce inflammation in the gut, improve motor control in mice with Huntington’s disease, and reduce intraocular pressure in rabbits with glaucoma. 

In terms of its effects on the brain, CBG has been shown to have unique properties compared to other cannabinoids. For example, it does not produce the psychoactive effects of THC, meaning that it does not result in a “high” when consumed. Additionally, CBG has been found to act as an antagonist at CB1 receptors, which are typically activated by THC. This means that it may have the potential to counteract some of the negative effects of THC, such as anxiety and paranoia, while still providing therapeutic benefits. 

Overall, while CBG is a relatively new area of study, the initial research suggests that it may have potentially therapeutic effects in a range of conditions. However, as with all cannabinoids, more research is needed to fully understand its effects on the brain and body, as well as to determine safe and effective dosage levels.